yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q26862828-0D124063-ABC2-4804-990B-9AC531344B38
Q26862828-0D124063-ABC2-4804-990B-9AC531344B38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26862828-0D124063-ABC2-4804-990B-9AC531344B38
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma
P2860
Q26862828-0D124063-ABC2-4804-990B-9AC531344B38
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26862828-0D124063-ABC2-4804-990B-9AC531344B38
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
dc72eff2fbae962de68401d20c383b299bee85f9
P2860
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.